期刊文献+

急诊PCI中血栓抽吸及不同途径给予替罗非班的临床研究 被引量:3

下载PDF
导出
摘要 目的:探讨在ST段抬高型心肌梗死直接经皮冠状动脉介入治疗(PCI)术中,血栓抽吸及不同途径给予替罗非班的急性期及远期效果。方法:99例心肌梗死患者按治疗方法不同分为单纯血栓抽吸(A)组、血栓抽吸+周围静脉替罗非班(B)组及血栓抽吸+梗死相关动脉内替罗非班组(C)组。观察各组术前及术后90min心电图ST段回落情况,肌酸肌酶同工酶(CK-MB)峰值,术后24h及术后6个月时左心室射血分数。随访患者的出血及心血管不良事件发生情况。结果:3组患者血栓抽吸后前向血流均达到TIMI3级。B组及C组术后90minST段回落、CK-MB峰值较A组降低,差异有统计学意义(P<0.05),B、C组术后90min ST段回落差异无统计学意义(P>0.05),但CK-MB峰值差异有统计学意义(P<0.05)。术后24hC组左心室射血分数高于B组及A组,差异有统计学意义(P<0.01),但术后6个月3组左心室射血分数比较差异无统计学意义(P>0.05)。3组患者随访期间均未发生出血及心血管不良事件。结论:血栓抽吸+替罗非班在改善心肌灌注、保护急性期左心功能方面优于单纯血栓抽吸,且梗死相关动脉内给药优于周围静脉给药;血栓抽吸及不同途径给予替罗非班对远期左心功能影响无差别。
机构地区 天津解放军
出处 《天津医药》 CAS 北大核心 2012年第11期1161-1163,共3页 Tianjin Medical Journal
  • 相关文献

参考文献1

二级参考文献1

共引文献24

同被引文献30

  • 1Hernanides RS, Ottervanger JP, ten Berg JM, et al. Net clinical benefitof prehospital glycoprotein Ⅱb/Ⅲa inhibitors in patients with STelevationmyocardial infarction and high risk of bleeding: effectof tirofiban in patients at high risk of bleeding using CRUSADEbleeding score[J]. J Invasive Cardiol, 2012, 24(3): 84-89.
  • 2Subherwal S, Bach RG, Chen AY, et al. Baseline risk of majorbleeding in non- ST elevation myocardial infarction[J].Circulation, 2009, 119(14): 1873-1882.
  • 3Rao AK, Pratt C, Berke A, et al. Thrombolysis in myocardialinfarction (TIMI) trial-phase I: hemorrhagic manifestationsand changes in plasma fibrinogen and the fibrinolytic system inpatients treated with recombinant tissue plasminogen activatorand streptokinase[J]. J Am Coll Cardiol, 1988, 11(1): 1-11.
  • 4Scarborough RM, Kleiman NS, Philips DR. Platelet glycoproteinⅡb/Ⅲa Antagonists. What are the relevant issues concerningtheir pharmacology and clinical use[J]? Circulation, 1999,100(4): 437-444.
  • 5van Werkum JW, Gerritsen WB, Kelder JC, et al. Inhibition ofplatelet function by abciximab or high-dose tirofiban in patientswith STEMI undergoing primary PCI: a randomised trial[J].Neth Heart J, 2007, 15(11): 375-381.
  • 6Platelet receptor inhibition in ischemic syndrome management(PRISM) study investigators. A comparison of aspirin plustirofiban with aspirin plus heparin for unstable angina[J]. N EnglJ Med, 1998, 338(21): 1498-1505.
  • 7The PRISM-PLUS Study Investigators. Inhibition of the plateletglycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable anginaand non-Q-wave myocardial infarction[J]. N Eng J Med, 1998,338(21): 1488-1497.
  • 8The RESTORE Investigators. Effects of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events inpatients with unstable angina or acute myocardial infarctionundergoing coronary angioplasty[J]. Circulation, 1997, 96(5):1445-1453.
  • 9Kochman W, Dobrzycki S, Nowak KS, et al. Safety and feasibilityof a noval dosing regimen of tirofiban administered in patientswith acute myocardial infarction with ST elevation beforeprimary coronary angioplasty: a pilot study[J]. J ThrombThrombolysis, 2004, 17(2): 127-131.
  • 10Hermanides RS, Ottervanger JP, Dambrink JHE, et al. Risk ofbleeding after pre-hospital administration of high dose tirofibanfor ST-elevation myocardial infarction[J]. Int J Cardiol, 2012,157(1): 86-90.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部